Sanofi Stock London S.E.

Equities

0A2V

US80105N1054

Pharmaceuticals

Market Closed - London S.E. 10:40:39 2023-10-27 EDT 5-day change 1st Jan Change
41.75 USD -21.08% Intraday chart for Sanofi -14.36% -15.81%

Financials

Sales 2024 * 46.33B 49.97B 68.13B Sales 2025 * 49.75B 53.66B 73.17B Capitalization 113B 122B 166B
Net income 2024 * 7.07B 7.62B 10.39B Net income 2025 * 8.57B 9.25B 12.61B EV / Sales 2024 * 2.59 x
Net Debt 2024 * 6.96B 7.51B 10.24B Net Debt 2025 * 2.53B 2.73B 3.72B EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
16.3 x
P/E ratio 2025 *
13.2 x
Employees 86,088
Yield 2024 *
4.29%
Yield 2025 *
4.51%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-21.08%
1 week-14.36%
Current month-14.14%
1 month-15.18%
3 months-13.10%
6 months-17.54%
Current year-15.81%
More quotes
1 week
41.75
Extreme 41.7487
49.67
1 month
41.75
Extreme 41.7487
49.69
Current year
41.75
Extreme 41.7487
52.77
1 year
41.75
Extreme 41.7487
55.67
3 years
36.99
Extreme 36.988
58.00
5 years
36.99
Extreme 36.988
58.00
10 years
36.99
Extreme 36.988
58.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-07-03 48.82 -0.04% 40,351
24-07-02 48.84 -1.29% 40,154
24-07-01 49.48 +1.75% 316
24-06-28 48.63 +1.28% 181
24-06-27 48.01 -1.51% 202

Delayed Quote London S.E., October 27, 2023 at 10:40 am

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
90.23 EUR
Average target price
108.1 EUR
Spread / Average Target
+19.79%
Consensus